Regatta Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Regatta Bio is a private, pre-clinical-stage biotech founded in 2021 and based in Boston, MA. The company is pioneering a platform for engineered Treg cell therapies designed to restore immune tolerance in transplantation and autoimmunity. Its pipeline features a de-risked strategy, starting with ex vivo expanded Tregs and advancing to genetically modified CAR-Tregs with enhanced features like IL-2 independence and resistance to standard immunosuppressants. Backed by incubators Eos BioInnovation and Panacea Venture, Regatta is positioned to address significant unmet needs in immune-mediated diseases.

TransplantationAutoimmune Diseases

Technology Platform

A proprietary platform for engineering regulatory T cells (Tregs), featuring ex vivo expansion (v1.0) and genetic modification to create CAR-Tregs with enhanced features like antigen-specific targeting (e.g., OX40L), IL-2 independence for persistence, and resistance to calcineurin inhibitors (CNIs) to function alongside standard immunosuppressants.

Opportunities

The large, underserved markets in chronic GvHD and solid organ transplantation, where current immunosuppressive therapies are inadequate and toxic, present a significant opportunity.

Regatta's engineered features, particularly CNI-resistance, offer a clear path to combination with standard of care and real-world adoption.

Success in transplantation could provide a strong foundation for expansion into the vast autoimmune disease market.

Risk Factors

Key risks include the technical and clinical challenges of demonstrating durable efficacy and safety for novel Treg therapies, regulatory hurdles for complex cell products, and intense competition from other biotechs in the immune tolerance space.

High manufacturing costs and future reimbursement challenges for autologous cell therapies also pose commercial risks.

Competitive Landscape

Regatta Bio competes in the emerging Treg cell therapy space with other private and public companies (e.g., Sangamo/Sanofi, GentiBio, Sonoma Biotherapeutics, Abata/Third Rock) and academic centers. Its differentiation hinges on specific platform features like CNI-resistance and IL-2 independence, which are designed to address practical clinical barriers in transplantation.

More companies in United States →